Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
about
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus diseaseSubcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesMultifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variantsIntravenous immunoglobulin as clinical immune-modulating therapy.Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.The pathogenesis of multifocal motor neuropathy and an update on current management options.Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Immunotherapy in Peripheral NeuropathiesTreatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registrySubcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.Evidence-based treatment of chronic immune-mediated neuropathies.Subcutaneous immunoglobulin: opportunities and outlook.Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatmentImmunotherapy of multifocal motor neuropathy.Indications and safety of intravenous and subcutaneous immunoglobulin therapy.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Bringing immunoglobulin knowledge up to date: how should we treat today?Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.Immune pathogenesis and treatment of multifocal motor neuropathy.Multifocal motor neuropathy: current therapies and novel strategies.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Subcutaneous IgG in neurologic diseases.The expanding role of therapeutic antibodies.Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.Outcome measures in MMN revisited: further improvement needed.New Frontiers in Subcutaneous Immunoglobulin Treatment.Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry.
P2860
Q24187946-B0E9A4BA-FAD0-418C-8207-54A94A575DB7Q26745685-E0E6FA7E-C288-449C-B86C-AE51B0A320A4Q26864907-A2E52F3F-DA87-4B74-96F2-FC2BECE4DC32Q28390264-BF71E570-DC55-4FBA-9D76-5405529DAB10Q33420267-48571C1F-C702-4B57-8C5C-BDCE48E2685EQ34457953-134B27C0-EA18-4800-A24E-AD7C7A3951B9Q34620111-E1AC8B13-7790-447C-86E1-E1B154181EE7Q35537340-9830CF29-5A5A-4F69-8BB3-178D23C5E18EQ35780802-0793B387-C2DB-406A-8364-D756C83E6029Q36094658-BC44B83A-5A3A-47BF-A3D0-C549A3D53693Q36484418-1CDB6403-498A-4B63-A1FE-1163970BF16BQ36737563-D709BC8F-E450-415A-B619-6E21999A2A3AQ37125900-7B656D5C-8777-48A8-9682-98C5D4ED87A9Q37550515-E56A698C-54D3-448D-90DC-F757CA6BB39AQ37626132-40B7627B-CDFB-40B5-9BA8-1293F662887CQ37696931-72B2AC6B-BC9C-495C-82C7-1F86A5296840Q37836898-E71066E5-C9F1-4A16-BDA5-EBF66115AD3CQ37877259-7EB161F6-E9D8-435A-B965-7FE0FCF1F215Q37890936-E890463A-8952-4545-9F8E-A6A6A6031B7BQ37901520-B30B8C87-37DC-448E-94C6-F5F0854125CEQ37959252-8514DD96-3648-419C-96BD-0DD4141D2D15Q38039965-D421F1FA-E472-4956-A64B-3159FDD77651Q38091664-D8ACEDBC-32ED-4F91-9F6E-E5A84B4E5AB0Q38152428-492AB987-98C4-4CC9-A95A-68DECE17EB7DQ38171572-DFAD952A-1F54-4942-A762-1214368469C3Q38182645-9CFCCC62-54FC-4BD8-9288-DFA451572F1AQ38228519-D28C36C0-4773-4542-B3AA-D9659216239EQ38270717-5E91BAB8-865A-4F40-84A6-C4B2C00591EDQ38820288-E44129F4-DDE3-42A3-AE3D-FCBA09E290F6Q39217483-9CE5BCE7-2D9D-4710-8B4A-678ACD3DEDF7Q39370917-F874D3A9-1C50-432A-960B-8233C9A6C862Q39604919-28F1F90F-4B97-4878-BDFC-EEA3A2E60E6BQ40793045-1F039A3B-3EB1-434C-99C0-1CBB072FFB49Q42775420-68C3C753-6C70-472C-85E6-EC70DB119DADQ44954147-58EDAA89-CB27-4E3E-A510-4C234A39090DQ45640650-56060C48-A38A-405A-8C93-ADC689DB7BB0Q47584292-EA2FA234-7727-4217-81D4-5D77D3603D8AQ47585442-CCFE0166-845B-4983-AF30-48123353BC12Q48301410-E25B7F58-152A-44AD-9ABC-79A14F9A58F5Q48387989-0002B7CA-5AFA-4493-9ADC-85F1965F0592
P2860
Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@ast
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@en
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@nl
type
label
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@ast
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@en
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@nl
prefLabel
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@ast
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@en
Subcutaneous versus intravenou ...... ngle-blinded cross-over trial.
@nl
P2093
P1476
Subcutaneous versus intravenou ...... ingle-blinded cross-over trial
@en
P2093
P2860
P304
P356
10.1111/J.1468-1331.2009.02568.X
P577
2009-02-19T00:00:00Z